NCT07282444

Brief Summary

This clinical trial tests a new way to share radiation therapy plans using the Collaborative Oncology between Radiologists and Radiation oncologists for the Evaluation of Contoured Targets (CORRECT) workflow to improve communication and collaboration between radiation oncologists (ROs) and radiologists when determining cancer targets for radiation treatment. Systemic barriers limit critical communication between radiation oncologists and radiologists and can lead to both under and overdosing of radiation therapy (RT) tumor targets and failures to properly interpret post-treatment imaging. The limited formal diagnostic radiology training of many providers can make differentiating normal from disease imaging findings during target determination difficult, especially in complex disease sites like the lung, head, and neck. Inaccurate target determination may result in cancer return, excess toxicity, or both. Likewise, radiologists who cannot access prior RT plans may mistake expected RT changes for recurrent cancer or overlook true progression. The CORRECT workflow was developed by ROs and radiologists to address RO-radiology communication barriers by facilitating sharing of comprehensive RT target contours during RT planning. The CORRECT workflow begins with the normal process of RO target contouring. Computed tomography (CT) images are then fused with RT targets and pushed to a pre-designated Picture Archiving and Communications System (PACS) software folder accessible by the radiology department. The radiologist can then review the fused images at their chosen time and annotate images to indicate potential deviations (e.g., not avoiding normal tissue or not including all tumor). The RO reviews the annotated images and decides if any changes to treatment targets are needed for the final treatment plan. Through this independent, asynchronous review of high-quality images, CORRECT overcomes many of the limitations of existing communication methods between RO-radiologist, fostering a more collaborative, efficient, and precise approach to cancer treatment planning.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
194

participants targeted

Target at P75+ for not_applicable

Timeline
28mo left

Started Jul 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 4, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 15, 2025

Completed
7 months until next milestone

Study Start

First participant enrolled

July 1, 2026

Expected
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2027

1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2028

Last Updated

March 23, 2026

Status Verified

March 1, 2026

Enrollment Period

1.3 years

First QC Date

December 4, 2025

Last Update Submit

March 20, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • The return of radiology feedback via Collaborative Oncology between Radiologists and Radiation oncologists for the Evaluation of Contoured Targets (CORRECT) (feasibility)

    If \> 50% of patients have target feedback returned to the radiation oncologist within 2 business days, this workflow will be considered feasible in community practice.

    Within 2 business days from receipt of initial radiation therapy (RT) targets

Secondary Outcomes (7)

  • Time (in business days) required to install the information technology (IT) application

    During study start-up prior to the enrollment of first patient case; up to 60 days after CIRB approval at the practice.

  • The number and proportion of cases per practice with reports of technical issues requiring centralized IT or CORRECT study team assistance

    During RT planning for each patient; over the 9 months of of patient accrual

  • Percentage of approached patients who declined consent

    During screening and enrollment over the 9 months of patient accrual

  • Acceptability of the CORRECT workflow.

    Up to 2 months after patient enrollment has concluded

  • Appropriateness of the CORRECT workflow

    Up to 2 months after patient enrollment has concluded

  • +2 more secondary outcomes

Study Arms (1)

Health Services Research (CORRECT workflow)

EXPERIMENTAL

ROs and radiologists receive training on the use of the CORRECT workflow and practice with test cases. ROs and radiologists then use the CORRECT workflow with patient cases for 12 months.

Behavioral: Training and EducationOther: Communication InterventionOther: Survey AdministrationOther: InterviewOther: Electronic Health Record Review

Interventions

Receive training and practice cases on CORRECT workflow

Health Services Research (CORRECT workflow)

Use CORRECT workflow

Health Services Research (CORRECT workflow)

Ancillary studies

Health Services Research (CORRECT workflow)

Ancillary studies

Health Services Research (CORRECT workflow)

Ancillary studies

Health Services Research (CORRECT workflow)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • PRACTICE: Must provide radiation therapy for ≥ 3 patients per month with lung cancer or head \& neck cancer
  • PRACTICE: At least one radiation oncologist and one radiologist (in house, contracted, etc.) at the practice willing to participate, but may have multiple participants at the practice
  • PRACTICE: Radiation oncologist/radiologist team must use Picture Archiving and Communication System (PACS) software at this practice
  • RADIATION ONCOLOGIST (NON-PATIENT): Must have been in independent practice (i.e., performing duties without preceptor oversight) for a minimum of six months
  • RADIATION ONCOLOGIST (NON-PATIENT): Must treat lung and/or head \& neck cancer patients with curative intent radiation therapy
  • RADIATION ONCOLOGIST (NON-PATIENT): Willing and able to participate in 15 minutes of mandatory virtual CORRECT training
  • RADIATION ONCOLOGIST (NON-PATIENT): Willing to participate in a 30-minute interview, if selected at the end of the study
  • RADIOLOGIST (NON-PATIENT): Must have been in independent practice (i.e., performing duties without preceptor oversight) for a minimum of six months
  • RADIOLOGIST (NON-PATIENT): Agree to review pre-treatment radiation therapy targets during the course of the study duration (approximately 12 months). Willing and able to participate in 15 minutes of mandatory virtual CORRECT training
  • RADIOLOGIST (NON-PATIENT): Willing to participate in a 30-minute interview, if selected at the end of the study
  • PATIENT: Must have any stage of clinically diagnosed lung or head \& neck (HN) cancer
  • PATIENT: Planned treatment with curative intent definitive RT (with or without other treatments). Curative intent RT must be documented in the electronic medical record (EMR) by the treating radiation oncologist
  • PATIENT: Must be expected to be treated by a radiation oncologist participating in this study
  • PATIENT: Must be 18 years or older

You may not qualify if:

  • PRACTICE: Participation by the Community Site or Minority/Underserved Community Site in another National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Cancer Care Delivery Research (CCDR) U34-supported protocol funded in NCI fiscal year 2025 or later. (Note: WF- 2301CD CONNECT is exempt from this policy, as it was funded prior to NCI fiscal year 2025.)
  • RADIATION ONCOLOGIST (NON-PATIENT): Planning to leave their position at this practice within the next 12 months
  • RADIATION ONCOLOGIST (NON-PATIENT): Providing service on a temporary basis (i.e., locum tenens providers)
  • RADIOLOGIST (NON-PATIENT): Planning to leave their position at this practice within the next 12 months
  • RADIOLOGIST (NON-PATIENT): Providing service on a temporary basis (i.e., locum tenens providers)
  • PATIENT: Unable to understand English or Spanish
  • PATIENT: Early glottic larynx cancer planned for definitive RT alone

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wake Forest NCORP Research Base

Winston-Salem, North Carolina, 27157, United States

Location

MeSH Terms

Conditions

Lung Neoplasms

Interventions

Educational StatusInterviews as Topic

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Socioeconomic FactorsPopulation CharacteristicsData CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Kathryn Weaver, PhD

    Wake Forest University Health Sciences

    STUDY CHAIR

Central Study Contacts

Karen Craver

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
No Data Available
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Model Details: No Data Available
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 4, 2025

First Posted

December 15, 2025

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

November 1, 2028

Last Updated

March 23, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.

Time Frame
6 months after publication for a 2 year duration
Access Criteria
upon request to NCORP@wfusm.edu
More information

Locations